The transcription factor GATA-6 regulates pathological cardiac hypertrophy

Circulation Research

Volumn 107, Issue 8, 2010, Pages 1032-1040

  Van Berlo, Jop H ^a   Elrod, John W ^a   Van Den Hoogenhof, Maarten M G ^a   York, Allen J ^a   Aronow, Bruce J ^a   Duncan, Stephen A ^c   Molkentin, Jeffery D ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

differentiation; genetically altered mice; heart; hypertrophy; transcription

Indexed keywords

MYOSIN HEAVY CHAIN BETA; TRANSCRIPTION FACTOR GATA 6;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENE TARGETING; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HOMEOSTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CARDIOMYOPATHY, DILATED; CELL DIFFERENTIATION; GATA4 TRANSCRIPTION FACTOR; GATA6 TRANSCRIPTION FACTOR; GENE DELETION; HEART FAILURE; HOMEOSTASIS; MICE; MICE, TRANSGENIC; TRANSCRIPTION, GENETIC;

EID: 77958468380     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.220764     Document Type: Article

References (30)

1. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068-3072. (Pubitemid 35440290)
2. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intra-cellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600.
3. Molkentin JD, Dorn GW II. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001;63:391-426.
4. Charron F, Tsimiklis G, Arcand M, Robitaille L, Liang Q, Molkentin JD, Meloche S, Nemer M. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev. 2001;15:2702-2719.
5. Liang Q, Wiese RJ, Bueno OF, Dai YS, Markham BE, Molkentin JD. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1-and 2-mediated phosphorylation of serine 105 in cardiomyo-cytes. Mol Cell Biol. 2001;21:7460-7469.
6. Hautala N, Tenhunen O, Szokodi I, Ruskoaho H. Direct left ventricular wall stretch activates GATA4 binding in perfused rat heart: involvement of autocrine/paracrine pathways. Pflugers Arch. 2002;443:362-369.
7. Hautala N, Tokola H, Luodonpaa M, Puhakka J, Romppanen H, Vuol-teenaho O, Ruskoaho H. Pressure overload increases GATA4 binding activity via endothelin-1. Circulation. 2001;103:730-735.
8. Molkentin JD, Lin Q, Duncan SA, Olson EN. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev. 1997;11:1061-1072.
9. Xin M, Davis CA, Molkentin JD, Lien CL, Duncan SA, Richardson JA, Olson EN. A threshold of GATA4 and GATA6 expression is required for cardiovascular development. Proc Natl Acad Sci \USA. 2006;103: 11189-11194.
10. Molkentin JD. The zinc finger-containing transcription factors GATA-4,-5, and-6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem. 2000;275:38949-38952.
11. Oka T, Xu J, Molkentin JD. Re-employment of developmental transcription factors in adult heart disease. Semin Cell Dev Biol. 2007;18: 117-131.
12. Pikkarainen S, Tokola H, Kerkela R, Ruskoaho H. GATA transcription factors in the developing and adult heart. Cardiovasc Res. 2004;63: 196-207.
13. Liang Q, De Windt LJ, Witt SA, Kimball TR, Markham BE, Molkentin JD. The transcription factors GATA4 and GATA6 regulate cardiomyo-cyte hypertrophy in vitro and in vivo. J Biol Chem. 2001;276: 30245-30253.
14. Heineke J, Auger-Messier M, Xu J, Oka T, Sargent MA, York A, Klevitsky R, Vaikunth S, Duncan SA, Aronow BJ, Robbins J, Crombleholme TM, Molkentin JD. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J Clin Invest. 2007;117:3198-3210.
15. Oka T, Maillet M, Watt AJ, Schwartz RJ, Aronow BJ, Duncan SA, Molkentin JD. Cardiac-specific deletion of GATA4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ Res. 2006;98:837-845.
16. Aries A, Paradis P, Lefebvre C, Schwartz RJ, Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci \USA. 2004;101:6975-6980.
17. Bisping E, Ikeda S, Kong SW, Tarnavski O, Bodyak N, McMullen JR, Rajagopal S, Son JK, Ma Q, Springer Z, Kang PM, Izumo S, Pu WT. GATA4 is required for maintenance of postnatal cardiac function and protection from pressure overload induced heart failure. Proc Natl Acad Sci \USA. 2006;103:14471-14476.
18. Sodhi CP, Li J, Duncan SA. Generation of mice harbouring a conditional loss-of-function allele of GATA6. BMC Dev Biol. 2006;6:19.
19. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, Robbins J. Reengi-neering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res. 2003;92:609-616.
20. Koutsourakis M, Langeveld A, Patient R, Beddington R, Grosveld F. The transcription factor GATA6 is essential for early extraembryonic development. Development. 1999;126:723-732.
21. Brewer A, Gove C, Davies A, McNulty C, Barrow D, Koutsourakis M, Farzaneh F, Pizzey J, Bomford A, Patient R. The human and mouse GATA-6 genes utilize two promoters and two initiation codons. J Biol Chem. 1999;274:38004-38016.
22. Takeda M, Obayashi K, Kobayashi A, Maeda M. A unique role of an amino terminal 16-residue region of long-type GATA-6. J Biochem. 2004;135:639-650.
23. Tamura T, Onodera T, Said S, Gerdes AM. Correlation of myocyte lengthening to chamber dilation in the spontaneously hypertensive heart failure (shhf) rat. J Mol Cell Cardiol. 1998;30:2175-2181.
24. Vandeput F, Wolda SL, Krall J, Hambleton R, Uher L, McCaw KN, Rad-wanski PB, Florio V, Movsesian MA. Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. J Biol Chem. 2007;282:32749-32757.
25. Feldman AM, Lorell BH, Reis SE. Trastuzumab in the treatment of meta-static breast cancer: anticancer therapy versus cardiotoxicity. Circulation. 2000;102:272-274.
26. Muto Y, Yoshioka T, Kimura M, Matsunami M, Saya H, Okano Y. An evolutionarily conserved leucine-rich repeat protein CLERC is a cen-trosomal protein required for spindle pole integrity. Cell Cycle. 2008;7: 2738-2748.
27. Le Goff C, Somerville RP, Kesteloot F, Powell K, Birk DE, Colige AC, Apte SS. Regulation of procollagen amino-propeptide processing during mouse embryogenesis by specialization of homologous ADAMTS proteases: insights on collagen biosynthesis and dermatosparaxis. Development. 2006; 133:1587-1596.
28. Zhao R, Watt AJ, Battle MA, Li J, Bondow BJ, Duncan SA. Loss of both GATA4 and GATA6 blocks cardiac myocyte differentiation and results in acardia in mice. Dev Biol. 2008;317:614-619.
29. Charron F, Paradis P, Bronchain O, Nemer G, Nemer M. Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. Mol Cell Biol. 1999;19:4355-4365.
30. Zeisberg EM, Ma Q, Juraszek AL, Moses K, Schwartz RJ, Izumo S, Pu WT. Morphogenesis of the right ventricle requires myocardial expression of GATA4. J Clin Invest. 2005;115:1522-1531.